Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755183 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
A Phase 2 study, sponsored by ORA.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00755183: Completed Phase 2 study, sponsored by ORA.
NCT00755183 is a Phase 2 study that has completed, run by ORA. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00755183, a Phase 2 study, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
Primary Outcome
The average of the secretion color, quality, and viscosity of the worst gland in the worst eye. All scales were numerical analog, 0-3, where 0=normal and 3=worst.
Interventions
- DRUG testosterone ophthalmic solution
- DRUG vehicle of testosterone ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00755183 record still lists
NCT00755183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which testosterone ophthalmic solution is the first listed.
NCT00755183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00755183 about?
NCT00755183 is a clinical study titled "Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction". The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
What is the current status of trial NCT00755183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00755183?
The interventions under investigation include: testosterone ophthalmic solution (DRUG), vehicle of testosterone ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00755183?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00755183's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia